Huma Raises $130M Series C to Scale Its 'Hospital at Home' Platform Globally
September 2, 2024
Huma, the London-headquartered digital health company, has raised $130 million in a Series C funding round to accelerate the global rollout of its remote patient monitoring platform. The round was co-led by Leaps by Bayer and Hitachi Ventures, with participation from Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, and HAT Technology & Innovation Fund. Notable individual investors including Nikesh Arora, former president of SoftBank, and Michael Diekmann, Chairman of Allianz, also joined the round. Goldman Sachs International acted as lead placement agent, with HSBC and Nomura serving as joint placement agents.
Founded in 2011 by Dan Vahdat and originally operating as Medopad, the company rebranded to Huma in 2020 as it shifted its focus from a narrow data-collection tool to a full remote care and clinical research platform. Vahdat built the company around the idea that healthcare systems and pharmaceutical companies needed a scalable, digital-first way to monitor patients outside of hospital settings — a thesis that the COVID-19 pandemic dramatically validated.
Huma's platform enables clinicians to monitor patients remotely through a mobile app, combined with wearable devices that track vital signs such as heart rate, blood oxygen saturation, and blood pressure. The system is used to power "virtual wards" — digital programmes that allow patients recovering from surgery or managing chronic conditions to be monitored at home — as well as to run decentralised clinical trials for pharmaceutical companies. During the pandemic, Huma partnered with the NHS to help manage patient cohorts and deploy oxygen saturation monitoring at scale, and also supported COVID-19 vaccine trials.
The company's business operates across two primary areas: healthcare provider partnerships, including substantial work with the NHS and health ministries in Germany and the UAE, and life sciences collaborations with major pharmaceutical firms. The platform has been shown to nearly double clinical capacity in some NHS settings and reduce hospital readmissions by over a third. Its combination of regulated software-as-a-medical-device capability with a flexible, modular architecture has made it attractive to both public health systems and commercial drug developers.
The $130 million raise — which the company originally planned to cap at $100 million before it was significantly oversubscribed — will be used to expand Huma's geographic reach into the United States, Asia, and the Middle East, deepen its R&D capabilities, and build out its life sciences partnerships. A further $70 million has been committed by investors contingent on milestone achievements, which Vahdat structured deliberately to ensure partners remain commercially engaged rather than passive shareholders.
Sources
Thank you to our Patrons & Partners:
